Skip to main content

Articles

Original Research
Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor
JoAnne Foody, MD; Robin S. Turpin, PhD; Beni A. Tidwell, BS; Debra Lawrence, PhD; Kathy L. Schulman, MS
Stakeholder Perspective
The Growing Role of Real-World Evidence in Clinical Decision-Making
Gary M. Owens, MD
Read More
Original Research, Practice Management
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, PhD; Maureen Neary, PhD, MS; Shang Li, MS; Ariel Rokito, BS; Hongbo Yang, PhD; Jipan Xie, MD, PhD; Al B. Benson III, MD, FACP, FASCO
Read More
Practice Management
The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers
Peter R. Fendt, PharmD, MBA; Brian Ung, PharmD, RPh; F. Randy Vogenberg, RPh, PhD
Read More
Original Research, Practice Management
The Cost of Hematopoietic Stem-Cell Transplantation in the United States
Michael S. Broder, MD, MSHS; Tiffany P. Quock, PhD, MS; Eunice Chang, PhD; Sheila R. Reddy, PhD, RPh; Rajni Agarwal-Hashmi, MD; Sally Arai, MD; Kathleen F. Villa, MS
Stakeholder Perspective
More Data Analysis Is Needed to Improve Outcomes, Lower Costs, and Maximize Appropriate Resource Use
James T. Kenney, RPh, MBA
Read More
Perspectives
Trending BIO
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers
Burton S. Brodsky, MD; Gary M. Owens, MD; Dennis J. Scotti, PhD, MBA; Keith A. Needham, BS; Christina L. Cool, MPH
Stakeholder Perspective
Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer
F. Randy Vogenberg, PhD, RPh
Read More
ACR 2017, Conference Correspondent
Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA
Read More
ACR 2017, Conference Correspondent
Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA
Read More
ACR 2017, Conference Correspondent
Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA
Read More
ACR 2017, Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Read More
Page 79 of 244
Results 781 - 790 of 2436